$102 Million

Chiasma

Initial Public Offering

Bookrunner, July 2015

Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. Chiasma offers its products in the United States.